Raymond James & Associates Scynexis Inc Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Scynexis Inc stock. As of the latest transaction made, Raymond James & Associates holds 17,394 shares of SCYX stock, worth $34,788. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,394
Previous 18,494
5.95%
Holding current value
$34,788
Previous $41,000
39.02%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding SCYX
# of Institutions
57Shares Held
15.4MCall Options Held
0Put Options Held
12.9K-
Federated Hermes, Inc. Pittsburgh, PA4.21MShares$8.43 Million0.01% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$4.47 Million0.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$3.38 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.45MShares$2.9 Million0.08% of portfolio
-
Amh Equity LTD660KShares$1.32 Million1.0% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $65.3M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...